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a  b  s  t  r  a  c  t
Insomnia  is  a  common  sleep  disorder  frequently  occurring  in  chronic  alcoholic  patients.  Neurobiological
basis  of insomnia,  as  well  as  of  alcoholism,  is associated  with  disrupted  functions  of the  main  neuro-
transmitter  systems,  including  the  serotonin  (5-hydroxytryptamine,  5-HT)  system.  Blood  platelets  are
considered  a  limited  peripheral  model  for  the  central  5-HT  neurons,  since  both  platelets  and  central  5-
HT  synaptosomes  have  similar  dynamics  of  5-HT.  Platelet  5-HT  concentration  and  platelet  monoamine
oxidase  type  B  (MAO-B)  are  assumed  to  represent  biomarkers  for particular  symptoms  and  behaviors
in psychiatric  disorders.  The  hypothesis  of this  study  was  that  platelet  5-HT  concentration  and  platelet
MAO-B  activity  will  be altered  in  chronic  alcoholic  patients  with  insomnia  compared  to  comparable  values
in patients  without  insomnia.  The  study  included  498  subjects:  395  male  and  103  female  medication-
free  patients  with  alcohol  dependence  and  502  healthy  control  subjects:  325  men  and  177  women.  The
effects  of  early,  middle  and  late insomnia  (evaluated  using  the  Hamilton  Depression  Rating  Scale),  as  well
as  sex,  age  and  smoking  on  platelet  5-HT  concentration  and  platelet  MAO-B  activity  were  evaluated  using
one-way  ANOVA  and  multiple  regression  analysis  by  the  stepwise  method.  Platelet  5-HT  concentration,
but  not  platelet  MAO-B  activity,  was  signiﬁcantly  reduced  in  alcoholic  patients  with  insomnia  compared
to  patients  without  insomnia.  Multiple  regression  analysis  revealed  that  platelet  5-HT  concentration  was
affected  by  middle  insomnia,  smoking  and  sex,  while  platelet  MAO  activity  was  affected  only  by  sex
and age.  The  present  and  previous  data  suggest  that platelet  5-HT  concentration  might  be  used,  after
controlling  for  sex  and  smoking,  as  a biomarker  for  insomnia  in alcoholism,  PTSD  and  in rotating  shift
workers.
© 2011 Elsevier Ireland Ltd. All rights reserved.
Patients with chronic alcoholism frequently experience sleep
disturbances such as insomnia, disrupted sleep, frequent episodes
of wakefulness, early wakening, and the reduced quality of life
[6,30]. Insomnia is present in 36–72% of alcoholic patients [1],
since chronic alcoholism affects sleep quality, and sleep is frag-
mented and restless [1].  Insomnia can be classiﬁed into early,
middle and late according to the Hamilton Depression Rating Scale
(HDRS) [11]. Neurobiological basis of insomnia, as well as of alco-
holism, is associated with disrupted functions of the main
Abbreviations: HDRS, Hamilton Depression Rating Scale; 5-HIAA, 5-
hydroxyindolacetic acid; MAO-B, monoamine oxidase type B; 5-hydroxytryptamine
5-HT, serotonin; 5-HTTLPR, serotonin transporter polymorphism.
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neurotransmitters systems such as serotonin (5-hydroxy-
tryptamine, 5-HT), noradrenalin and histamine. Wakefulness
is related to increased 5-HT activity from dorsal raphe [33].
Altered function of the 5-HT system is associated with devel-
opment of alcoholism, alcohol addiction, alcohol abuse [15,29],
and sleep apnea [18], insomnia [34], arousal, sleep–waking
states, vigilance behaviors, synchronization of the biological
clock and circadian rhythm [34], while sleep disturbances are
affected by antidepressants [1].  Insomnia is related to mood
instabilities, craving, alcoholic relapse and heavy drinking in
chronic alcoholic patients [6].  Prolonged insomnia may lead to
self medication with alcohol and chronic alcoholism, while, on
the other hand, toxic effects of alcohol in the brain of chronic
alcoholics may  lead to insomnia [6,30].  Blood platelets are con-
sidered as a non-invasive and inexpensive peripheral model for
the studies of the central 5-HT neurons, since both platelets
and central 5-HT synaptosomes have similar uptake, storage,
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Table 1
Age, platelet 5-HT concentration and platelet MAO-B activity in healthy subjects and alcoholic patients subdivided according to the sex and smoking status.
Men  Women
Smokers Non-smokers Smokers Non-smokers
Age (years)a
Healthy subjects (N = 502) 39.30 (10.02) N = 95 47.09 (13.02) N = 230 44.44 (8.91) N = 39 58.83 (17.52) N = 138
Alcoholic patients (N = 498) 48.48 (947)* N = 238 50.50 (10.39) N = 157 47.76 (9.03) N = 58 57.16 (12.30) N = 45
Platelet 5-HT (nmol/mg proteins)b
Healthy subjects (N = 502) 1.09 (0.44) N = 95 0.94 (0.41) N = 230 1.14 (0.47) N = 39 1.10 (0.46) N = 138
Alcoholic patients (N = 498) 0.91 (0.49)* N = 238 0.71 (0.41)** N = 157 0.84 (0.43)*** N = 58 0.61 (0.29)**** N = 45
MAO-B activity (nmol 4 OHQ/mg proteins/h)c
Healthy subjects (N = 502) 13.13 (6.16) N = 95 17.00 (8.63) N = 230 18.60 (8.73) N = 39 22.63 (10.63) N = 138
Alcoholic patients (N = 498) 17.34 (9.20)* N = 238 18.72 (9.86) N = 157 20.76 (10.75) N = 58 24.01 (11.76) N = 45
N is the number of subjects.
a F(7,992) = 27.191; p < 0.001.
b F(7,992) = 15.39; p < 0.001.
c F(7,992) = 12.37; p < 0.001.
* p = 0.028–001 vs. healthy male smokers (one-way ANOVAs followed by Tukey’s test).
** p = 0.028–0.001 vs. healthy male non-smokers (one-way ANOVAs followed by Tukey’s test).
*** p = 0.001 vs. healthy female smokers (one-way ANOVAs followed by Tukey’s test).
**** p = 0.019 vs. healthy female non-smokers (one-way ANOVAs followed by Tukey’s test).
release and metabolism of 5-HT [7,12].  Platelet 5-HT concentra-
tion has been proposed as a marker of the central serotonergic
function [8,10] and a biomarker for particular symptoms and
behaviors in psychiatric disorders [35], although this proposal
has also been challenged [20]. Platelet monoamine oxidase type
B (MAO-B) has similar biochemical and pharmacological char-
acteristics with the brain MAO-B [22], and was  proposed as a
marker for the central serotonergic system [22]. Altered platelet
MAO-B activity was associated with different psychopathologies
and personality traits, vulnerability to drug-abuse, addiction,
social mal-adaptation, and dysinhibitory psychopathology [22].
Lower concentration of platelet 5-HT has been demonstrated in
chronic alcoholic patients compared to healthy control subjects
[23,26,31],  while lower [22], as well as unaltered [25] platelet
MAO-B activity was found in alcoholic compared to control
subjects. Rotating shift workers with sleep disturbances had
lower platelet 5-HT concentration compared to day workers [32],
while no data evaluating either platelet 5-HT or platelet MAO-B
activity and insomnia in alcoholism has been published thus
far. Since chronic alcoholics frequently suffer from insomnia [1],
and both platelet markers are under the inﬂuence of sex and
smoking [21,22], the hypothesis of the study was  that platelet
5-HT and MAO-B would differ between patients with chronic
alcoholism with or without insomnia. The aim of the study was
to evaluate platelet 5-HT concentration and platelet MAO-B
activity in alcoholic patients subdivided according to the smoking
status, sex and presence and/or absence of early, middle or late
insomnia.
The study included 498 subjects: 395 male (49.5 years old, range
23–77) and 103 female (52.5 years old, range 23–84) medication-
free patients with chronic alcoholism. The diagnosis of alcohol
dependency was done using the Structured Clinical Interview for
DSM-IV [9] based on DSM-IV criteria [5].  The comparative healthy
control group consisted of 502 subjects: 325 male (45.0 years
old, range 23–90) and 177 female (55.6 years old, range 23–89)
medication-free subjects, with no personal or family history of
psychopathology and/or substance abuse or dependence, no hep-
atic or renal disorders, and alcohol-free for at least 24 h. Patients
were admitted into Psychiatric Hospital Vrapce due to the with-
drawal syndrome related to alcohol dependency. Since most of the
patients were acutely intoxicated with alcohol, the interview and
the sampling were done at least 12 h after the admission at the
department, when the patients were sober, with their full coop-
eration and adequate understanding. Written informed consent
was obtained from all subjects, under procedures approved by the
Ethics Committees of the Psychiatric Hospital Vrapce, and Uni-
versity Hospital Center Zagreb, Zagreb, Croatia. Study has been
performed in accordance with the ethical standards laid down
in the 1964 Declaration of Helsinki. All subjects were subdivided
according to the smoking status (into smokers and non-smokers).
Alcoholic patients were subdivided according to the items 4 (early
insomnia), 5 (middle insomnia) and 6 (late insomnia) of the HDRS
[11] into patients without (with score 0) or with (i.e. with scores
1–2) early, middle or late insomnia; or without and with insomnia
(including early, middle and late insomnia). Blood samples (8 ml)
were collected into plastic syringes with 2 ml of acid citrate dex-
trose anticoagulant at 08.00 h. The determination of the platelet
5-HT concentration was done in platelet rich plasma using spec-
troﬂuorimetric method, as previously described [24,27]. Platelet
protein concentrations were measured by the method according to
Lowry et al. [16]. Platelet MAO-B activity was determined spec-
troﬂuorimetrically using kynuramine as a substrate by a slight
modiﬁcation of the method developed by Krajl [14], as previously
described [23]. The results, expressed as means (standard devia-
tion), were evaluated using one-way analysis of variance (ANOVA)
followed by Tukey’s test and multiple regression analysis by the
stepwise method (with predictor variables of insomnia (none, early,
middle, late), smoking (non-smoker, smoker), sex (male, female),
and age). The level of signiﬁcance was set at p = 0.05.
Age, platelet 5-HT concentration and platelet MAO-B activity
were signiﬁcantly different (one-way ANOVA and Tukey’s test)
between alcoholic patients and healthy control subjects subdivided
according to the sex and smoking status (Table 1). Male alco-
holic smokers were signiﬁcantly (p = 0.001) older than healthy male
smokers, while other groups were matched for age. Male (p = 0.028)
and female (p = 0.019) alcoholic smokers had signiﬁcantly lower
platelet 5-HT concentration than healthy male or female smok-
ers, and male or female alcoholic non-smokers had signiﬁcantly
(p = 0.001) lower platelet 5-HT values than healthy male or female
non-smokers. Platelet MAO-B activity was  signiﬁcantly (p = 0.005)
higher in male alcoholic smokers compared to male healthy smok-
ers (Table 1).
Early (72 and 71%), middle (68 and 67%) and late (38 and
41%) insomnia occurred at similar frequency in male and female
alcoholic patients, respectively (Figs. 1 and 2). To determine the
association between the dependent variables such as platelet 5-
HT concentration (Fig. 1) or platelet MAO-B activity (Fig. 2), and
the potential predictor variables (age, sex, smoking status and the
presence or absence of early, middle or late insomnia), multiple
regression analyses were conducted separately for patients with or
Author's personal copy
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Fig. 1. Platelet 5-HT concentration (mean ± SD) in alcoholic patients without insomnia and alcoholic patients with early, middle and late insomnia, subdivided according to
the  sex and smoking status. Numbers in parentheses are the number of subjects. Statistical evaluation of the data is presented in Table 2. *p = 0.001 vs. the corresponding
smokers; **p = 0.001 vs. alcoholic patients without insomnia (multiple regression analysis).
without early, middle and late insomnia (Table 2). Multiple regres-
sion analyses for platelet 5-HT (signiﬁcance shown in Fig. 1) as
a dependent variable revealed that: (1) smoking status (but not
sex, age or early insomnia) signiﬁcantly (p = 0.001) predicted 4.9%
of the variance in platelet 5-HT concentration; (2) smoking sta-
tus and the presence or absence of middle insomnia (but not sex
and age) signiﬁcantly (p = 0.032) predicted 5.5% of the variance in
platelet 5-HT concentration, and (3) smoking status and sex (but
not age or late insomnia) signiﬁcantly (p = 0.044) predicted 8.8%
of differences in 5-HT values. Multiple regression analyses with
platelet MAO-B activity (signiﬁcance shown in Fig. 2) as a depen-
dent variable showed that: (1) sex and age (but not early insomnia
or smoking) signiﬁcantly predicted 4.4% of the variance (p = 0.018)
of the enzyme activity, (2) sex and age (but not middle insomnia or
smoking) signiﬁcantly predicted 5.8% of the variance (p = 0.038) in
platelet MAO-B, and (3) sex, but not age, smoking or late insomnia,
signiﬁcantly (p = 0.005) predicted 2.9% variance in platelet MAO-B
values (Table 2). Our collective data reveal that platelet 5-HT con-
centration, but not platelet MAO-B activity, was signiﬁcantly lower
in alcoholic patients with middle insomnia.
Fig. 2. Platelet MAO-B activity (mean ± SD) in alcoholic patients without insomnia
and alcoholic patients with early, middle and late insomnia, subdivided according
to  the sex and smoking status. Numbers in parentheses are the number of subjects.
Statistical evaluation of the data is presented in Table 2. *p = 0.005–0.001 vs. the
corresponding male patients (multiple regression analysis).
To further corroborate the signiﬁcant effect of middle insomnia
on dependent variables, multiple regression analyses were used
to re-evaluate the inﬂuence of the age, sex, smoking status and
the presence or absence of insomnia (not subdivided into early,
middle or late) on platelet 5-HT concentration or platelet MAO-
B activity. Analysis conﬁrmed a signiﬁcant (R2 = 0.060; adjusted
R2 = 0.057; F(2,495) = 15.888; p = 0.001) effect of the presence of
insomnia (t = − 2.019; p = 0.001) and smoking (t = 5.315; p = 0.001)
on platelet 5-HT concentration. In contrast, platelet MAO-B activity
was  signiﬁcantly (R2 = 0.041; adjusted R2 = 0.037; F(2,495) = 10.519;
p = 0.001) affected by sex (t = 3.690; p = 0.001) and age (t = 2.334;
p = 0.020), but not by presence or absence of insomnia.
Major ﬁndings from our study were: (1) alcoholic patients with
insomnia (or explicitly with middle insomnia) had signiﬁcantly
lower platelet 5-HT concentration than alcoholic patients without
insomnia; (2) the presence of early, middle or late insomnia did not
inﬂuence platelet MAO-B activity in alcoholic patients; (3) smoking
signiﬁcantly affected platelet 5-HT concentration, and (4) sex and
age signiﬁcantly affected platelet MAO-B activity.
Patients with chronic alcoholism or alcohol abuse frequently
(36–72%) suffer from insomnia [1,6,30]. Central 5-HT regulates
arousal states, wakefulness, synchronization of the biological clock
and circadian rhythm, and alterations of these behaviors may lead
to insomnia and sleep disturbances [4].  Platelet 5-HT concentration
was  lower in rotating shift workers when compared to day workers
[32]. We have found lower platelet 5-HT concentration in alcoholic
patients with evident middle insomnia (evaluated using HDRS) in
comparison to alcoholic patients without middle insomnia. These
results were conﬁrmed by the analysis showing that the presence
of insomnia (not subdivided into early, middle and late) was signif-
icantly associated with platelet 5-HT concentration. These results
are in line with the lower platelet 5-HT values, lower levels of the
5-HT metabolite, 5-hydroxyindolacetic acid (5-HIAA), and higher
frequency of the short allele of the serotonin transporter polymor-
phism (5-HTTLPR) found in workers who work in rotation shifts
compared to day workers [32]. The present study did not evalu-
ate the distribution of the 5-HTTLPR variants in alcoholic patients
with insomnia, since platelet 5-HT concentration is not affected by
the 5-HTTLPR genotypes [27,32]. Although three types of insomnia
occurred similarly in male and female patients, our present and pre-
vious [28] results show the lack of effect of late insomnia on platelet
5-HT concentration in alcoholic patients, male or female patients
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Table 2
Results of stepwise multiple regression analysis for variables predicting platelet 5-HT concentration and platelet MAO-B activity.
Variable B Std. error  ˇ coefﬁcient t Sig.
Platelet 5-HT concentration (nmol/mg protein)
Early insomniaa
Constant 0.692 0.034 20.528 p < 0.001
Smoking status 0.207 0.044 0.221 4.730 p < 0.001
Middle  insomniab
Constant 0.785 0.057 13.714 p < 0.001
Smoking status 0.201 0.045 0.213 4.459 p < 0.001
Middle  insomnia −0.122 0.057 −0.032 −2.150 p < 0.001
Late  insomniac
Constant 0.706 0.050 14.170 p < 0.001
Smoking status 0.263 0.059 0.260 4.437 p < 0.001
Gender −0.141  0.070 −0.119 −2.023 p = 0.044
Platelet  MAO-B activity (nmol 4HOQ/mg protein/h)
Early insomniad
Constant 12.715 2.350 5.410 p < 0.001
Gender  4.179 1.182 0.167 3.536 p < 0.001
Age 0.110 0.047 0.122 2.371 p = 0.018
Middle  insomniae
Constant 12.743 2.396 5.317 p < 0.001
Gender  5.153 1.193 0.208 4.320 p < 0.001
Age  0.099 0.047 0.100 2.081 p = 0.038
Late  insomniaf
Constant 17.567 0.689 25.482 p < 0.001
Gender 4.139 1.465 0.170 2.825 p = 0.005
From the independent variables calculated in this regression (age, sex, smoking status and the presence or absence of early, middle or late insomnia), those listed in table
were  signiﬁcantly associated with platelet 5-HT concentration and platelet MAO  activity at the indicated level of signiﬁcance in the model.
a Fit of the model: R2 = 0.049; adjusted R2 = 0.047; df = 1,434; F = 22.370; p < 0.001.
b Fit of the model: R2 = 0.055; adjusted R2 = 0.050; df = 1,413; F = 4.624; p = 0.032.
c Fit of the model: R2 = .088; adjusted R2 = .081; df = 1,268; F = 4.093; p = 0.044.
d Fit of the model: R2 = 0.044; adjusted R2 = 0.040; df = 1,433; F = 5.621; p = 0.018.
e Fit of the model: R2 = 0.058; adjusted R2 = 0.053; df = 1,413; F = 4.331; p = 0.038.
f Fit of the model: R2 = .029; adjusted R2 = .025; df = 1,269; F = 7.982; p = 0.005.
on dialysis with chronic renal failure [24], or in male veterans with
posttraumatic stress disorder (PTSD) [19]. The differences between
the aforementioned studies were that these subjects were not cat-
egorized according to the smoking status. Our results concur with
our preliminary data showing lower platelet 5-HT concentration
in the smaller number of male alcoholics with middle insomnia
(who were not subdivided according to the smoking status), and in
male PTSD veterans with insomnia and ﬂashbacks [28], compared
to groups without sleep disturbances. Platelet 5-HT concentration
was not affected by medication, age, comorbid diagnoses or sui-
cidal attempts, since the present study included medication-free
alcoholic patients; the effect of age was not signiﬁcant; and comor-
bid psychiatric disorders or suicide attempts were reported to be
devoid of any signiﬁcant effect on platelet 5-HT concentration in
male or female alcoholic patients [21]. The frequency of smok-
ing was similar between male (60%) and female (56%) alcoholics.
The ﬁnding that male alcoholic smokers have higher platelet 5-
HT concentration than male alcoholic non-smokers agrees with
previously published data [21,31].  The lack of clear sex related dif-
ferences in platelet 5-HT concentration is in contrast with some
previous data, presumably due to the fact that alcoholic patients
were not subdivided according to the smoking status [23,26,28],
but this ﬁnding is in line with the previous studies after subdivi-
sion according to the smoking status [21]. Reduced platelet 5-HT
concentration was found in alcoholic subjects compared to healthy
control subjects [21,23,26];  but in addition, the present study con-
ﬁrmed signiﬁcantly lower platelet 5-HT values in male and female
alcoholic smokers and non-smokers compared to corresponding
healthy male and female smokers and nonsmokers. This ﬁnding
stresses the need of subdividing data according to the smoking
status, since smoking signiﬁcantly affected platelet 5-HT values in
male and female alcoholic patients with or without insomnia.
In line with our previous preliminary ﬁndings showing the
lack of effect of various sleep disturbances on platelet MAO  activ-
ity in much smaller groups of chronic alcoholic patients, combat
exposed veterans with PTSD, or patients with major depressive
disorder [28], we have found that the presence of early, middle
or late insomnia did not change platelet MAO-B activity in male or
female alcoholic patients. In contrast to our present and previously
published data [28], higher platelet MAO-B activity was found in
depressed patients with late insomnia [2],  and in alcoholics dur-
ing the recovery period after withdrawal from heavy alcohol abuse
with fatigue, insomnia and reduced sleep [3] compared to corre-
sponding controls. However, the data on the smoking status were
not reported in these older studies. Platelet MAO-B activity was
signiﬁcantly affected by sex and age, as expected [22], but not by
smoking, although the substances from the cigarette smoke reduce
platelet MAO-B activity [22,31]. Platelet MAO-B activity was simi-
lar between alcoholic patients and healthy subjects, higher in male
alcoholic smokers when compared to healthy male smokers, but
was  not signiﬁcantly affected by insomnia, medication (present
study), or comorbid psychiatric diagnoses [23].
The reduced prefrontal 5-HT activity was  associated with dis-
turbed sleep–wakefulness rhythm and loss of emotional control
[13], while maximal 5-HT activity is achieved during waking [33].
Low central 5-HT activity is related to development of aggres-
sive and impulsive behavior [17], that frequently occurs in chronic
alcoholic patients. Although reductions in platelet 5-HT concentra-
tion, decreases in 5-HIAA levels and over-expression of the short
allele of the 5-HTTLPR polymorphism [32] were found in rotation
shift workers (who have disturbed sleep patterns) compared to
daily workers, our present data do not conﬁrm the hypothesis that
platelet MAO-B activity (proposed to reﬂect the activity of the cen-
tral 5-HT system [22]), might be used as a peripheral biomarker
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of the insomnia. In contrast, although platelet 5-HT concentration
does not reﬂect central 5-HT activity, platelet 5-HT concentration
was signiﬁcantly and inversely associated with middle insomnia in
alcoholic patients.
Present and previous results [28,32] suggest that platelet 5-HT
concentration might be used, after controlling for smoking and sex,
as a peripheral biomarker for insomnia in alcoholism, PTSD and in
rotating shift workers.
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